Interim analysis of a phase II trial in 30 men with up to five PSMA-positive metastases from CRPC: PSA progression within 1 year was 44% with metastasis-directed radiotherapy vs 75% with observation (not significant, P=0.14); median time to progression 12.4 vs 2.9 months.
RCTn = 30
Hölscher et al. Ablative radiotherapy in castration-resistant prostate cancer